Contineum Therapeutics (Contineum Therapeutics) Long-Term Debt : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Long-Term Debt?

Contineum Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.

Contineum Therapeutics's annual Long-Term Debt declined from Dec. 2021 ($3.66 Mil) to Dec. 2022 ($0.00 Mil) but then stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Contineum Therapeutics Long-Term Debt Historical Data

The historical data trend for Contineum Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Long-Term Debt Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Long-Term Debt

3.66

Contineum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial			-	-	-	-	-

Contineum Therapeutics (NAS:CTNM) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Contineum Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024